Morrisville, United States
Novan, Inc. is a medical dermatology company founded in 2008, with a primary focus on researching, developing, and commercializing innovative therapeutic products for skin diseases. The company's goal is to deliver safe and efficacious therapies to patients, addressing unmet medical needs. Novan is currently developing SB206 (berdazimer gel, 10.3%) as a topical prescription gel for the treatment of viral skin infections, specifically molluscum contagiosum.
In a significant move, Novan recently completed the acquisition of EPI Health, enhancing its commercial infrastructure across sales, marketing, and communications, and expanding its market access and pharmacy relations capabilities. Following this acquisition, the company employs approximately 100 staff, including sales personnel covering 42 territories, and promotes products for plaque psoriasis, rosacea, acne, and dermatoses. Additionally, Novan has a pipeline of potential product candidates utilizing its proprietary nitric oxide-based technology platform, NITRICIL™, aiming to develop new treatments for multiple indications.
The company operates within the Biotechnology and Health Care industries and is headquartered in the United States. Its last investment was a $15.00M Post-IPO Debt investment on 17 July 2023, provided by Ligand Pharmaceuticals.
